Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPASS 2-AD
2025-521624-30-00Phase 2Completed
- Sponsor
- Bluefin Biomedicine
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of BFB759 in atopic dermatitis (AD) (3 arms), sponsored by Bluefin Biomedicine. Primary endpoint: Percent change from baseline in EASI at Week 16. Started Jan 2026; status: completed.
02
Drugs
BFB759
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-521624-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521624-30-00.